| 摘要 |
2083391 9117770 PCTABS00008 The present invention relates to the use of combinations of antibody therapy and chemotherapy in the treatment of malignant disease. It is based in part, on observation so if the surprising effectiveness of combination therapy; several patients who had received the anti-tumor antibody L6 or MG21 achieved complete remission in response to subsequent chemotherapy, although the same patients had not responded to similar chemotherapy regimens prior to receiving L6 or MG21 antibody treatment. Embodiments of the invention, antiglycolipid antibodies such as, preferably, L6 monoclonal antibody or MG21 monoclonal antibody, are administered to patients who are subsequently treated with standard chemotherapy regimens. In preferred embodiments of the invention, chemotherapy is administered within several months of antibody treatment. It is suggested that the effectiveness of combination therapy may be attributable to antibodies at the tumor site which render the malignant cells more susceptible to the toxic effects of chemotherapeutic agents.
|
